Literature DB >> 30423329

Resident Memory and Recirculating Memory T Cells Cooperate to Maintain Disease in a Mouse Model of Vitiligo.

Jillian M Richmond1, James P Strassner1, Mehdi Rashighi1, Priti Agarwal1, Madhuri Garg1, Kingsley I Essien1, Lila S Pell1, John E Harris2.   

Abstract

Tissue resident memory T cells (Trm) form in the skin in vitiligo and persist to maintain disease, as white spots often recur rapidly after discontinuing therapy. We and others have recently described melanocyte-specific autoreactive Trm in vitiligo lesions. Here, we characterize the functional relationship between Trm and recirculating memory T cells (Tcm) in our vitiligo mouse model. We found that both Trm and Tcm sensed autoantigen in the skin long after stabilization of disease, producing IFN-γ, CXCL9, and CXCL10. Blockade of Tcm recruitment to the skin with FTY720 or depletion of Tcm with low-dose Thy1.1 antibody reversed disease, indicating that Trm cooperate with Tcm to maintain disease. Taken together, our data provide characterization of skin memory T cells in vitiligo, demonstrate that Trm and Tcm work together during disease, and indicate that targeting their survival or function may provide novel, durable treatment options for patients.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30423329      PMCID: PMC6431571          DOI: 10.1016/j.jid.2018.10.032

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  54 in total

1.  CD44-deficient mice develop normally with changes in subpopulations and recirculation of lymphocyte subsets.

Authors:  U Protin; T Schweighoffer; W Jochum; F Hilberg
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

2.  Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients.

Authors:  Susan R Schwab; João P Pereira; Mehrdad Matloubian; Ying Xu; Yong Huang; Jason G Cyster
Journal:  Science       Date:  2005-09-09       Impact factor: 47.728

3.  FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory.

Authors:  D D Pinschewer; A F Ochsenbein; B Odermatt; V Brinkmann; H Hengartner; R M Zinkernagel
Journal:  J Immunol       Date:  2000-06-01       Impact factor: 5.422

4.  IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking.

Authors:  Jennifer H Dufour; Michelle Dziejman; Michael T Liu; Josephine H Leung; Thomas E Lane; Andrew D Luster
Journal:  J Immunol       Date:  2002-04-01       Impact factor: 5.422

5.  Mucosal T lymphocyte numbers are selectively reduced in integrin alpha E (CD103)-deficient mice.

Authors:  M P Schön; A Arya; E A Murphy; C M Adams; U G Strauch; W W Agace; J Marsal; J P Donohue; H Her; D R Beier; S Olson; L Lefrancois; M B Brenner; M J Grusby; C M Parker
Journal:  J Immunol       Date:  1999-06-01       Impact factor: 5.422

Review 6.  FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.

Authors:  Kenji Chiba
Journal:  Pharmacol Ther       Date:  2005-06-13       Impact factor: 12.310

7.  Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides.

Authors:  E Jäger; M Maeurer; H Höhn; J Karbach; D Jäger; Z Zidianakis; A Bakhshandeh-Bath; J Orth; C Neukirch; A Necker; T E Reichert; A Knuth
Journal:  Int J Cancer       Date:  2000-05-15       Impact factor: 7.396

8.  The CXC chemokine murine monokine induced by IFN-gamma (CXC chemokine ligand 9) is made by APCs, targets lymphocytes including activated B cells, and supports antibody responses to a bacterial pathogen in vivo.

Authors:  Matthew K Park; Doron Amichay; Paul Love; Elizabeth Wick; Fang Liao; Alex Grinberg; Ronald L Rabin; Hongwei H Zhang; Senkuta Gebeyehu; Timothy M Wright; Akiko Iwasaki; Youmin Weng; Julie A DeMartino; Karen L Elkins; Joshua M Farber
Journal:  J Immunol       Date:  2002-08-01       Impact factor: 5.422

9.  High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals.

Authors:  M J Pittet; D Valmori; P R Dunbar; D E Speiser; D Liénard; F Lejeune; K Fleischhauer; V Cerundolo; J C Cerottini; P Romero
Journal:  J Exp Med       Date:  1999-09-06       Impact factor: 14.307

10.  Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

Authors:  Willem W Overwijk; Marc R Theoret; Steven E Finkelstein; Deborah R Surman; Laurina A de Jong; Florry A Vyth-Dreese; Trees A Dellemijn; Paul A Antony; Paul J Spiess; Douglas C Palmer; David M Heimann; Christopher A Klebanoff; Zhiya Yu; Leroy N Hwang; Lionel Feigenbaum; Ada M Kruisbeek; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2003-08-18       Impact factor: 14.307

View more
  30 in total

1.  Clinical characteristics of pediatric hidradenitis suppurativa: a cross-sectional multicenter study of 140 patients.

Authors:  Peter Theut Riis; Ditte Marie Saunte; Viktoria Sigsgaard; Axel Patrice Villani; Philippe Guillem; José C Pascual; Naomi N Kappe; Annika M J D Vanlaerhoven; Hessel H van der Zee; Errol P Prens; Moetaz El-Domyati; Hossam Abdel-Wahab; Nayera Moftah; Rania Abdelghani; Eugenia Agut-Busquet; Jorge Romaní; Carol Hlela; Lerinza van den Worm; Vincenzo Bettoli; Giada Calamo; Mehmet Ali Gürer; Burcu Beksaç; Lukasz Matusiak; Amelia Glowaczewska; Jacek C Szepietowski; Lennart Emtestam; Jan Lapins; Hassan Riad Kottb; Mohammad Fatani; Lisa Weibel; Martin Theiler; Maïa Delage-Toriel; Thi Thanh Hong Lam; Aude Nassif; Pierre-Andre Becherel; Mateja Dolenc-Voljc; Nejib Doss; Dorra Bouazzi; Farida Benhadou; Veronique Del Marmol; Gregor B E Jemec
Journal:  Arch Dermatol Res       Date:  2020-03-12       Impact factor: 3.017

2.  Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma.

Authors:  Henry T Quach; Anna K Dewan; Elizabeth J Davis; Kristin K Ancell; Run Fan; Fei Ye; Douglas B Johnson
Journal:  JAMA Oncol       Date:  2019-06-01       Impact factor: 31.777

Review 3.  Tissue-resident lymphocytes: from adaptive to innate immunity.

Authors:  Haoyu Sun; Cheng Sun; Weihua Xiao; Rui Sun
Journal:  Cell Mol Immunol       Date:  2019-01-11       Impact factor: 11.530

Review 4.  T-cell positioning by chemokines in autoimmune skin diseases.

Authors:  Jillian M Richmond; James P Strassner; Kingsley I Essien; John E Harris
Journal:  Immunol Rev       Date:  2019-05       Impact factor: 12.988

Review 5.  The Role of Memory CD8+ T Cells in Vitiligo.

Authors:  Rebecca L Riding; John E Harris
Journal:  J Immunol       Date:  2019-07-01       Impact factor: 5.422

Review 6.  Tissue-resident memory T cells in the skin.

Authors:  Samar Khalil; Tara Bardawil; Mazen Kurban; Ossama Abbas
Journal:  Inflamm Res       Date:  2020-01-27       Impact factor: 4.575

7.  Anatomically distinct fibroblast subsets determine skin autoimmune patterns.

Authors:  Zijian Xu; Daoming Chen; Yucheng Hu; Kaiju Jiang; Huanwei Huang; Yingxue Du; Wenbo Wu; Jiawen Wang; Jianhua Sui; Wenhui Wang; Long Zhang; Shuli Li; Chunying Li; Yong Yang; Jianmin Chang; Ting Chen
Journal:  Nature       Date:  2021-12-15       Impact factor: 49.962

Review 8.  Tissue-resident memory T cells and their biological characteristics in the recurrence of inflammatory skin disorders.

Authors:  Ling Chen; Zhu Shen
Journal:  Cell Mol Immunol       Date:  2019-10-08       Impact factor: 11.530

Review 9.  Pathophysiology of Skin Resident Memory T Cells.

Authors:  Yoshiki Tokura; Pawit Phadungsaksawasdi; Kazuo Kurihara; Toshiharu Fujiyama; Tetsuya Honda
Journal:  Front Immunol       Date:  2021-02-03       Impact factor: 7.561

Review 10.  Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo.

Authors:  Yinghan Wang; Shuli Li; Chunying Li
Journal:  Clin Rev Allergy Immunol       Date:  2021-07-20       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.